Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
May 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
Sep 14, 2024 · Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.
Targeting HER2-positive breast cancer: advances and future …
Nov 7, 2022 · The dependence of the tumour on HER2, coupled with effective HER2-targeted drugs such as trastuzumab, pertuzumab and most recently, tucatinib and trastuzumab deruxtecan (T-DXd), have...
FDA Approves First Targeted Drug To Treat HER2-Low Breast …
Jun 5, 2022 · Trastuzumab (Herceptin®) was the first targeted therapy developed to treat HER2-positive patients. “HER2-positive,” which accounts for 15% to 20% of all breast cancers, means there is a high level of the HER2 protein on the surface of cancer cells, driving tumor growth.
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
Jul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
meaningful progression-free survival improvement - AstraZeneca
Apr 29, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu approved in the US as first tumour-agnostic HER2 …
Apr 6, 2024 · AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.
FDA grants accelerated approval to fam-trastuzumab deruxtecan …
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...
Enhertu demonstrated clinically meaningful survival across …
Oct 23, 2023 · Enhertu (6.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial and/or DESTINY-Gastric02 trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for …
Mar 23, 2022 · Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated with trastuzumab and a taxane, as well as with ...